drugset / Trial / NCT01129427

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

NCT01129427

Phase 1 Completed 66 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedCrossoverDouble-blindBasic science

Summary

Primary objective: * Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with pantoprazole 80 mg/day compared to given alone in healthy male subjects * Compare the pharmacokinetic profiles of clopidogrel active metabolite when clopidogrel is given either alone or concomitantly with pantoprazole Secondary Objective: * Compare the pharmacokinetic profiles of clopidogrel when clopidogrel is given either alone or concomitantly with pantoprazole

Timeline

Start
2009-08
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject Pantoprazole Other / unclassified 80 mg Oral

Indications

No indication recorded.